Skip to main content

Table 5 Costs of management of adverse events attributed to chemotherapy

From: Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment)

  National tariff ENCC Adjusted ENCC
All ADRs – Annual per capita costs
 Pre-progression (N = 1223 patients)
  Base case € 3729 € 3947 € 3915
  Survival-corrected € 3979 € 4212 € 4177
 Post-progression (N = 1354 patients)
  Base case € 5474 € 5452 € 5631
  Survival-corrected € 8582 € 8546 € 8827
Individual ADRs (both progression stages combined) – Mean cost per stay with ADRa
 Infections (N = 1090 stays) € 3936 ± 4328 € 4184 ± 4301 € 4214 ± 4451
 Neutropenia (N = 225 stays) € 3806 ± 3920 € 4115 ± 3877 € 3946 ± 3988
 Glomerulonephritis (N = 41 stays) € 3456 ± 3552 € 3713 ± 4099 € 3698 ± 4017
 Myalgia/pain (N = 309 stays) € 3032 ± 4609 € 2580 ± 2213 € 2940 ± 4468
 Colitis (N = 93 stays) € 2942 ± 2114 € 3107 ± 2078 € 3105 ± 2130
 Diarrhoea (N = 40 stays) € 2747 ± 3036 € 3043 ± 4158 € 3104 ± 4376
 Decreased blood ACTH (N = 34 stays) € 2607 ± 2725 € 2410 ± 1907 € 2454 ± 2143
 Fatigue (N = 268 stays) € 2567 ± 2817 € 2405 ± 1771 € 2541 ± 2549
 Skin reactions (N = 137 stays) € 2333 ± 2544 € 2278 ± 1647 € 2398 ± 2514
 Dyspnoea (N = 56 stays) € 1875 ± 1508 € 1896 ± 1487 € 1918 ± 1512
 Anaemia (N = 660 stays) € 1645 ± 2510 € 1726 ± 1554 € 1791 ± 2370
 Nausea/vomiting (N = 42 stays) € 1302 ± 703 € 1539 ± 796 € 1532 ± 792
 Thrombocytopenia (N = 208 stays) € 1252 ± 1432 € 1929 ± 2159 € 1392 ± 1330
 Basocellular carcinoma (N = 2599 stays) € 1129 ± 2671 € 1073 ± 1922 € 1116 ± 2553
 Neuropathies (N = 15 stays) € 691 ± 597 € 1489 ± 610 € 808 ± 586
  1. aMean costs are calculated for the total number of stays related to each individual ADR and are presented with their standard deviations. ENCC: Études Nationales de Coûts à Méthodologie Commune